Three Conferences, One Location!
Seventh Annual Novel Vaccines
Vaccine leaders from around the world will once again come together to discuss critical issues surrounding the development of effective – and affordable – vaccines at the Seventh Annual Novel Vaccines meeting. Day One will explore innovative approaches to conquering infectious diseases including Hepatitis, Dengue Fever and Influenza. Day Two will be devoted to “the Big 3” – HIV, Malaria and Tuberculosis – and the highlighted Plenary Session on Day Three will explore predicting immune response through emerging technologies such as Systems Biology approaches. The Novel Vaccines meeting examines the successful vaccine achievements that respond to the most pernicious diseases threatening humankind. This meeting not only provides a snapshot of where vaccine innovation stands today, but also gives vaccine professionals the opportunity to network, establish collaborations, and learn from leaders in the field.
Inaugural Vaccine Quality throughout the Life Cycle
This event brings together specialists from Process Development, Analytical Characterization, CMC, and Regulatory Strategy amongst others to examine the important interface between the process, vaccine characterization, and interaction with the regulatory authorities. Attendees will discover how the experts adapt the process and set up panels of characterization tests for robust potency assays, physicochemical characterization, and for release. We plan to cover all stages of development, a range of prophylactic areas, a selection of cell lines and a variety of vaccines.
Fourth Annual Adjuvants & Delivery Systems
Adjuvants and Novel Delivery Systems are widely accepted as key to creating more efficacious vaccines with improved methods for storage and delivery. This leading vaccine meeting addresses the ongoing achievements of creating the next generation of vaccines, including toll-like receptor technology and DNA vaccines. Though lack of FDA approval for new adjuvants presents a major hurdle, researchers continue to delineate adjuvants’ mode of action in the quest to improve vaccines for human use. In the Adjuvants & Delivery Systems meeting, vaccine leaders will discuss their innovative work that is creating a new era of advanced vaccines.
For more information, please visit http://www.imvacs.com/
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. www.chicorporate.com
For more information:
Cambridge Healthtech Institute